Founder Lodge | Aro Biotherapeutics raises $41,500,000 at Series B …

Nov 29, 2023  · Aro Biotherapeutics raises $41,500,000 at Series B on 2023-11-29 in Biotechnology, industry founded/co-founded by Susan Dillon


Install CouponFollow Chrome Extension   CouponFollow Extension

$41500000
OFF

Founder Lodge | Aro Biotherapeutics Raises $41,500,000 At Series B …

3 weeks from now

Nov 29, 2023  · Aro Biotherapeutics raises $41,500,000 at Series B on 2023-11-29 in Biotechnology, industry founded/co-founded by Susan Dillon

founderlodge.com

$41
OFF

Aro Biotherapeutics Secures $41.5M Series B Financing

3 weeks from now

Philadelphia, PA, November 28, 2023 --- Aro Biotherapeutics, a clinical stage biotechnology company pioneering the development of tissue-targeted genetic medicines, today announced …

arobiotx.com

$41
OFF

Aro Biotherapeutics Secures $41.5M Series B Financing - Yahoo …

3 weeks from now

PHILADELPHIA, November 28, 2023--Aro Biotherapeutics, a clinical stage biotechnology company pioneering the development of tissue-targeted genetic medicines, today announced …

yahoo.com

$41
OFF

Aro Biotherapeutics Raises $41.5M Series B Financing - Finsmes.com

3 weeks from now

Nov 28, 2023  · Aro Biotherapeutics, a Philadelphia, PA-based clinical stage biotechnology company, raised $41.5M in Series B funding. The round was led by Cowen Healthcare …

finsmes.com

$177
OFF

Aro Biotherapeutics - Raised $177M Funding From 8 Investors

3 weeks from now

Jan 23, 2025  · How much funding did Aro Biotherapeutics raise in its latest funding round? Aro Biotherapeutics raised $41.5M in its latest funding round, which was Series B round held on …

tracxn.com

$41500000
OFF

Series B - Aro Biotherapeutics - 2023-11-28 - Crunchbase

3 weeks from now

Nov 28, 2023  · Aro Biotherapeutics raised $41500000 on 2023-11-28 in Series B

crunchbase.com

$41500000
OFF

Founder Lodge | Pandion Raises $41,500,000 At Series B On 2024 …

3 weeks from now

22/03/2024 Series B $41,500,000 We are a technology-first transportation provider. Tailor-made for e-commerce, we deliver a high performing one-day and two-day delivery experience for all. …

founderlodge.com

$41500000
OFF

Founder Lodge | Method Raises $41,500,000 At Series B On 2025 …

3 weeks from now

24/01/2025 Series B $41,500,000 Method Financial empowers real-time data and payment access for consumer liabilities. Using consumer’s consent, Method can securely connect all of …

founderlodge.com

$41
OFF

Aro Biotherapeutics Secures $41.5M Series B Financing

3 weeks from now

Nov 30, 2023  · Aro Biotherapeutics, a clinical stage biotechnology company pioneering the development of tissue-targeted genetic medicines, announced it has secured $41.5M in a …

pharmajournalist.com

$55000000
OFF

Founder Lodge | Asher Biotherapeutics Raises $55,000,000 At Series …

3 weeks from now

17/04/2024 Series C $55,000,000 Asher Bio is a biotechnology company developing precisely targeted immunotherapies for cancer and other diseases. Our cis-targeting platform aims to …

founderlodge.com

$3
OFF

Founder Lodge | 225+ Founders $3.2B Raised’s Post - LinkedIn

3 weeks from now

Asher Biotherapeutics raised $55,000,000 in Series C-Congrats Craig Gibbs Full Round Info: https://lnkd.in/gMXgXJqN Round Investors: RA Capital Management…

linkedin.com

$105000000
OFF

Founder Lodge | Attovia Therapeutics Raises $105,000,000 At Series …

3 weeks from now

14/05/2024 Series B $105,000,000 Attovia is creating a pipeline of biotherapeutics with an initial focus on immune-mediated disease and oncology. We leverage ATTOBODY, a novel …

founderlodge.com

$88
OFF

Aro Biotherapeutics Raises $88M In Series A Financing

3 weeks from now

Jan 5, 2021  · Aro Biotherapeutics, a Philadelphia, PA-based biotechnology company pioneering the development of tissue-targeted genetic medicines, closed an $88m Series A financing.

finsmes.com

$135000000
OFF

Founder Lodge | Latigo Biotherapeutics, Inc. Raises $135,000,000 At ...

3 weeks from now

15/02/2024 Series A $135,000,000 Latigo Biotherapeutics Inc., headquartered in Thousand Oaks, CA, is a privately held clinical-stage biotechnology company developing best-in-class non …

founderlodge.com

$41500000
OFF

Founder Lodge | Soleus Capital Management, L.P. Raises …

3 weeks from now

Feb 15, 2022  · Soleus Capital Management, L.P. raises $41,500,000 at Series B on 2022-02-15 in Investment Management, industry founded/co-founded by Lennox Ketner

founderlodge.com

$80000000
OFF

Founder Lodge | A2 Biotherapeutics, Inc. Raises $80,000,000 At …

3 weeks from now

Jan 10, 2025  · A2 Biotherapeutics, Inc. raises $80,000,000 at Series C on 2025-01-10 in Biotechnology Research, industry founded/co-founded by Jim Robinson

founderlodge.com

FAQs about Founder Lodge | Aro Biotherapeutics raises $41,500,000 at Series B … Coupon?

Who are Aro Biotherapeutics co-founders?

Aro Biotherapeutics co-founders Karyn O'Neil (left) and Susan Dillon. Aro Biotherapeutics raised $41.5 million from a private stock sale in its second major equity financing this year. The Philadelphia biotechnology company’s Series B funding round was led by Cowen Healthcare Investments. ...

Who funded Aro biotechnology?

The Philadelphia biotechnology company’s Series B funding round was led by Cowen Healthcare Investments. Aro, founded in 2018 by former Johnson & Johnson executives Susan Dillon and Karyn O'Neil, is focused on developing tissue-targeting genetic medicines. ...

How much money did Aro raise in 2021?

In January, Aro raised $24 million in the initial close of the Series B financing, with Cowen also serving as the lead investor. Also participating in the company's latest financing were JJDC Inc., Northpond Ventures, Healthcap and BVF Partners, all of whom were also investors in the company’s $88 million Series A round in 2021. ...

Where is Aro based?

Aro, which has its headquarters in The Curtis at 6th and Walnut streets in Center City, holds an exclusive worldwide license for centyrin protein therapeutics, which were discovered by O’Neil and her team at Janssen Pharmaceutical Cos., a division of Johnson & Johnson (NYSE: JNJ). ...

Will Aro use abx1100 to treat Pompe disease?

Aro plans to use the proceeds to advance the development of its lead new drug candidate, ABX1100, as a potential treatment for patients with Pompe disease. ...

Install CouponFollow Extension on Chrome

Install the CouponFollow extension to search for discount codes when shopping the fastest!

Install CouponFollow Chrome Extension   Install CouponFollow Chrome Extension